Galmed Pharmaceuticals (GLMD) Income from Non-Controlling Interests (2016 - 2026)
Galmed Pharmaceuticals (GLMD) posted quarterly Income from Non-Controlling Interests of $80000.0 for Q1 2026, up 521.05% year-over-year from $12881.4 in Q1 2025, and up 521.05% quarter-over-quarter from -$19000.0 in Q1 2025.
Galmed Pharmaceuticals (GLMD) Income from Non-Controlling Interests (2016 - 2026) Analysis & Trends
Galmed Pharmaceuticals' Income from Non-Controlling Interests history runs 10 years deep, the most recent figure standing at $80000.0 for Q1 2026.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Inc. Minority (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 63.60 Mn |
| 10 | Galmed Pharmaceuticals | 2.31 Mn | -9.57 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 80,000.00 |
| Mar 31, 2025 | -19,000.00 |
| Mar 31, 2024 | 1,000.00 |
| Sep 30, 2023 | -55,000.00 |
| Mar 31, 2023 | -100,000.00 |
| Sep 30, 2022 | -106,000.00 |
| Mar 31, 2022 | 445,000.00 |
| Sep 30, 2021 | 183.00 Mn |
| Mar 31, 2021 | 130,000.00 |
| Sep 30, 2020 | 408,000.00 |
| Jun 30, 2020 | -725,000.00 |
| Jun 30, 2019 | -16,000.00 |
| Mar 31, 2017 | -24,000.00 |
| Mar 31, 2016 | -46,000.00 |